Search results

AbbVie (ABBV) is one of the stocks most watched by Zacks.com visitors lately. So, it might be a good idea to review some of the factors that might affect the near-term performance of the stock.

Over

The market expects AbbVie (ABBV) to deliver a year-over-year increase in earnings on higher revenues when it reports results for the quarter ended March 2026. This widely-known consensus outlook is

Wall Street analysts expect AbbVie (ABBV) to post quarterly earnings of $2.69 per share in its upcoming report, which indicates a year-over-year increase of 9.4%. Revenues are expected to be

AbbVie ABBV is set to report first-quarter 2026 results on April 29, with investor focus likely to remain on its immunology segment. Following the loss of exclusivity (LoE) for its flagship drug

Pfizer PFE and AbbVie ABBV are leading U.S. drugmakers with strong positions across multiple therapeutic areas. Oncology contributes roughly 27% of Pfizer’s total revenues, while the company also

AbbVie ABBV is set to report first-quarter 2026 results on April 29. While the company’s immunology portfolio will remain the primary focus, its neuroscience segment is expected to contribute

AbbVie ABBV stock is currently trading below its 50-day and 200-day simple moving averages (SMAs). A stock trading below both its 50-day and 200-day simple moving averages is generally viewed as

AbbVie ABBV is set to report first-quarter 2026 results on April 29, before the opening bell. While the immunology segment is expected to remain the company’s primary growth driver, the oncology

AbbVie ABBV is set to report first-quarter 2026 earnings on April 29, before the opening bell. The Zacks Consensus Estimate for sales and earnings is pegged at $14.78 billion and $2.69 per share

AbbVie ABBV announced that the FDA has issued a complete response letter (CRL) to the biologics license application (BLA) seeking approval of its fast-acting short-duration toxin

Taking full advantage of the stock market and investing with confidence are common goals for new and old investors, and Zacks Premium offers many different ways to do both.

The popular research

Abbott (ABT) closed the most recent trading day at $103.56, moving +1.7% from the previous trading session. The stock's change was less than the S&P 500's daily gain of 2.51%. Elsewhere, the Dow saw

Wall Street expects a year-over-year increase in earnings on higher revenues when Abbott (ABT) reports results for the quarter ended March 2026. While this widely-known consensus outlook is

The upcoming report from Abbott (ABT) is expected to reveal quarterly earnings of $1.14 per share, indicating an increase of 4.6% compared to the year-ago period. Analysts forecast revenues of

Abbott (ABT) came out with quarterly earnings of $1.15 per share, beating the Zacks Consensus Estimate of $1.14 per share. This compares to earnings of $1.09 per share a year ago. These figures are

Abbott (ABT) reported $11.16 billion in revenue for the quarter ended March 2026, representing a year-over-year increase of 7.8%. EPS of $1.15 for the same period compares to $1.09 a year ago.

The

Abbott Laboratories ABT reported first-quarter 2026 adjusted earnings per share (EPS) of $1.15, which surpassed the Zacks Consensus Estimate by 0.6%. The figure improved 5.5% from the prior-year

Founded in 1929, Lord Abbett managed assets worth more than $ 250 billion as of March 31, 2026. This privately held company has around 184 investment professionals with an average of 18 years of